Analysis of antiarrhythmic drug concentrations determined during electrophysiologic drug testing in patients with inducible tachycardias

Berry, Nada S.; Bauman, Jerry L.; Gallastegui, Jose; Bauma, W. D.; Beckman, Karen J.; Hariman, Robert J.

doi:10.1016/0002-9149(88)90376-1

Cited by 8 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whereas, it has been reported that these effects by malarial compounds are due to activation of K channels (Guo et al, 1995), our studies suggest clinically relevant direct interactions between antimalarial compounds and SERT which can impact serotonergic system. Estimates of both quinidine and quinine concentrations calculated from measured blood levels in humans suggest that blood quinidine concentrations can rise to 9.5 μM in patients treated for arrhythmia (Berry et al, 1988) and in humans treated with quinine blood levels can range from 6.2–32.1 μM (Pussard et al, 1999; White, 1985). Based on our studies, these levels are sufficient to inhibit the serotonin transporter.…”

Section: Discussionmentioning

confidence: 99%

Stereoselective inhibition of serotonin transporters by antimalarial compounds

Beckman

Pramod

Perley

et al. 2014

Neurochemistry International

View full text Add to dashboard Cite

The serotonin (5-HT) transporter (SERT) is an integral membrane protein that functions to reuptake 5-HT released into the synapse following neurotransmission. This role serves an important regulatory mechanism in neuronal homeostasis. Previous studies have demonstrated that several clinically important antimalarial compounds inhibit serotonin (5-hydroxytryptamine, 5-HT) reuptake. In this study, we examined the details of antimalarial inhibition of 5-HT transport in both Drosophila (dSERT) and human SERT (hSERT) using electrophysiologic, biochemical and computational approaches. We found that the cinchona alkaloids quinidine and cinchonine, which have identical stereochemistry about carbons 8 and 9, exhibited the greatest inhibition of dSERT and hSERT transporter function whereas quinine and cinchonidine, enantiomers of quinidine and cinchonine, respectively, were weaker inhibitors of dSERT and hSERT. Furthermore, SERT mutations known to decrease the binding affinity of many antidepressants affected the cinchona alkaloids in a stereo-specific manner where the similar inhibitory profiles for quinine and cinchonidine (8S,9R) were distinct from quinidine and cinchonine (8R,9S). Small molecule docking studies with hSERT homology models predict that quinine and cinchonidine bind to the central 5-HT binding site (S1) whereas quinidine and cinchonine bind to the S2 site. Taken together, the data presented here support binding of cinchona alkaloids to two different sites on SERT defined by their stereochemistry which implies separate modes of transporter inhibition. Notably, the most potent antimalarial inhibitors of SERT appear to preferentially bind to the S2 site. Our findings provide important insight related to how this class of drugs can modulate the serotonergic system as well as identify compounds that may discriminate between the S1 and S2 binding sites and serve as lead compounds for novel SERT inhibitors.

show abstract